- Technology and Data
- Front End Sales and Marketing
- Allergy
- HIV
- Women's Health
- Migraine
- Compounding
- Continuous Glucose Monitoring
- Mental Health Awareness
- Veterinary Pharmacy
- CBD
- Infectious Disease
- Eye Health
- Digestive Health
- Biosimilars
- Influenza
- Shingles
- COPD Management
- Pediatrics
- Generics
- Pain Management
- COVID-19
- Immunization
- Oncology
- Anticoagulants
- Autoimmune Diseases
- Dermatology
- Diabetes
- Respiratory
- Heart Health
- Cardiovascular Clinical Consult
Multipronged Approach Improves Asthma Outcomes in Children
An investigation examines whether an intervention including both school and home components improves asthma outcomes.
Asthma is a fairly common disease in childhood and previous research has shown that Black children with asthma have worse morbidity and mortality than their non-minority peers with the disease. A number of the children who are at risk of poorer outcomes participate in Head Start programs. An investigation in JAMA Pediatrics examines whether a multilevel asthma education program in both the home and asthma led to improved asthma control when compared to a school-based only program.1
Researchers run a randomized clinical trial that included children with asthma who were enrolled in a Head Start program in Baltimore, Maryland. The children and their primary caregivers were recruited between April 2011 and November 2016. The intervention used was the Asthma Basic Care (ABC) family education combined with Head Start asthma education and was compared with Head Start asthma education alone. They measured asthma control via the Test for Respiratory and Asthma Control in Kids (TRACK) score.
A total of 398 children were included in the research, with 247 boys and an average age of 4.2 years. The investigators found that the children who were enrolled in the ABC plus Head Start program had reduced courses of oral corticosteroids corticosteroids (β = −0.61; 95% CI, −1.13 to −0.09; P = .02), improved asthma control (β = 6.26; 95% CI, 1.77 to 10.75; P < .001), as well as a reduction in hospitalizations (odds ratio, 0.36; 95% CI, 0.21-0.61; P < .001) during the course of a 12-month period.
Read the full article on Contemporary Pediatrics.
COPD Exacerbations Reduced Substantially With Dupilumab, Phase 3 Data Shows
November 27th 2023The NOTUS trial was shown to have successfully achieved its primary endpoint, demonstrating the notable efficacy of dupilumab in reducing exacerbations by 34% versus placebo in individuals with moderate-to-severe COPD showing evidence of type 2 inflammation.
FDA, CDC Increase Availability of RSV Monoclonal Antibody for Infants
November 23rd 2023The federal agencies said that they will continue to work closely with manufacturers to maintain the availability of the vaccines through the end of 2023 and early 2024 to meet the demand during the RSV season.
Moderna COVID-19 Vaccine Dosing Errors in Pediatric Population Prompt FDA Response
November 7th 2023The FDA is advising health care professionals who administer the vaccine to make sure the correct volume of the vaccine is withdrawn from the vial and the correct dose is administered to the patient.
